Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

Código QR

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

Katrine B Hansen1, Tina Vilsbøll2, Filip K Knop21Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DenmarkAbstract: Type 2 diabetes mellitus...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Knop FK, Hansen K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Glucagon-like peptide-1 (GLP-1) exenatide liraglutide type 2 diabetes. Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/d61d2987502242fb852f12ca9e997c17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell R, et al.
Publicado: (2019)

The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review
por: Katrine B Hansen, et al.
Publicado: (2010)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Mechanisms of neuroprotective action of incretin mimetics
por: Timur Dmitrievich Vlasov, et al.
Publicado: (2016)

Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day
por: Igor A. Sklyanik, et al.
Publicado: (2021)

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
por: Orme ME, et al.
Publicado: (2017)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
por: Yang P, et al.
Publicado: (2019)

Simultaneous Effect of Resveratrol and Probiotics on Insulin Resistance and Glucagon-Like Peptide (GLP-1) Levels in Diabetic Rats
por: A Pegah, et al.
Publicado: (2021)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
por: Pearson S, et al.
Publicado: (2019)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
por: Ekaterina Alekseevna Shestakova
Publicado: (2011)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney H, et al.
Publicado: (2017)

Incretins today: multiple effects and therapeutic potential
por: Oksana V. Tsygankova, et al.
Publicado: (2019)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary J, et al.
Publicado: (2010)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019)

Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?
por: Khoury Johad, et al.
Publicado: (2018)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz S
Publicado: (2010)

The Association Between Femoral Artery Intima-Media Thickness and Serum Glucagon-Like Peptide-1 Levels Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus
por: Le TD, et al.
Publicado: (2020)

Incretin-based therapy: renal effects
por: Anton Ivanovich Korbut, et al.
Publicado: (2016)

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
por: Martin AA, et al.
Publicado: (2016)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders WB, et al.
Publicado: (2016)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
por: Lee J, et al.
Publicado: (2019)

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
por: Funch D, et al.
Publicado: (2021)

Is there an association between liraglutide use and female breast cancer in a real-world setting?
por: Funch D, et al.
Publicado: (2018)

Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021)

Corrigendum: Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019)

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
por: Yanbin Dong, et al.
Publicado: (2021)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020)

Elevated Glucagon-like Peptide-1 and a Th2 Shift May Support Reduced Prevalence of Thoracic Aortic Aneurysm in Patients with Diabetes
por: Stelia Ntika, et al.
Publicado: (2021)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao Q, et al.
Publicado: (2016)

To Assess Liraglutide’s Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System
por: Yin J, et al.
Publicado: (2021)

Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology
por: Guo Q, et al.
Publicado: (2021)